-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Background: Metformin is the first-line drug for the treatment of type 2 diabetes
Metformin treatment can reduce the level of oxidative stress in patients with type 2 diabetes
Upon admission, record demographic information (age, gender, race/ethnicity, body mass index (BMI), province), comorbidities and risk factors (smoking, drinking, diabetes course, hypertension, dyslipidemia, atrial fibrillation, coronary heart disease, Coagulation disorders, hyperhomocysteinemia, family history of stroke and transient ischemic attack [TIA]), pre-stroke (antihypertensive, antiplatelet drugs, statins, insulin therapy and metformin therapy) and acute Period treatment
Results: We included 730 patients for analysis (median age: 65 years [IQR, 56-72] years, 57.
The median hematoma volume of MET(+) patients was lower than that of the MET(-) group .
Figure 1 Baseline cerebral hemorrhage in patients with MET(+) and MET(-)
Figure 1 Baseline cerebral hemorrhage in patients with MET(+) and MET(-)
Table: Discharge and follow-up of patients with cerebral hemorrhage
Table: Discharge and follow-up of patients with cerebral hemorrhage
Figure 2 Kaplan Meier curve of 1-year all-cause mortality of patients using MET (n=241) and patients not using MET (n=358)
Figure 2 Kaplan Meier curve of 1-year all-cause mortality of patients using MET (n=241) and patients not using MET (n=358)
Figure 3 The MRS scores of the survivors within 1 year after admission were stratified by MET usage
Figure 3 The MRS scores of the survivors within 1 year after admission were stratified by MET usage
In patients with diabetic intracerebral hemorrhage, the use of metformin before intracerebral hemorrhage has nothing to do with hospital mortality and one-year prognosis
Tu WJ, Zeng Q, Wang K,et al.
Prestroke Metformin Use on the 1-Year Prognosis of Intracerebral Hemorrhage Patients with Type 2 Diabetes.
Leave a message here